메뉴 건너뛰기




Volumn 13, Issue 2, 2008, Pages 319-334

Clinical implications of resistance to antiretrovirals: New resistance technologies and interpretations

Author keywords

[No Author keywords available]

Indexed keywords

ACH 806; ALPHA INTERFERON; AMPRENAVIR; ANTIRETROVIRUS AGENT; ATAZANAVIR; CHEMOKINE RECEPTOR CCR5 ANTAGONIST; DARUNAVIR; EFAVIRENZ; ELVITEGRAVIR; ENFUVIRTIDE; ETRAVIRINE; GAG PROTEIN; GS 9132; INDINAVIR; INTEGRASE INHIBITOR; LOPINAVIR; MARAVIROC; NELFINAVIR; NEVIRAPINE; PROTEINASE INHIBITOR; RALTEGRAVIR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; RO 1752; STAVUDINE; TENOFOVIR; UNCLASSIFIED DRUG; UNINDEXED DRUG; VICRIVIROC; VIRUS RNA; ZIDOVUDINE;

EID: 42149183706     PISSN: 13596535     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper
Times cited : (7)

References (57)
  • 1
    • 37249065868 scopus 로고    scopus 로고
    • Resistance to the HIV-integrase inhibitor raltegravir: Analysis of protocol 005, a Phase II study in patients with triple-class resistant HIV-1 infection
    • Hazuda DJ, Miller MD, Nguyen BY, Zhao J. Resistance to the HIV-integrase inhibitor raltegravir: analysis of protocol 005, a Phase II study in patients with triple-class resistant HIV-1 infection. Antivir Ther 2007; 12:S10.
    • (2007) Antivir Ther , vol.12
    • Hazuda, D.J.1    Miller, M.D.2    Nguyen, B.Y.3    Zhao, J.4
  • 2
    • 40549125135 scopus 로고    scopus 로고
    • Resistance and cross-resistance to first generation integrase inhibitors: Insights from a phase II study of elvitegravir (GS-9137)
    • McColl DJ, Fransen S, Gupta S, et al. Resistance and cross-resistance to first generation integrase inhibitors: insights from a phase II study of elvitegravir (GS-9137). Antivir Ther 2007; 12:S11.
    • (2007) Antivir Ther , vol.12
    • McColl, D.J.1    Fransen, S.2    Gupta, S.3
  • 3
    • 34347353118 scopus 로고    scopus 로고
    • Impact of baseline NNRTI mutations on the virological response to TMC125 in the phase III clinical trials DUET-1 and DUET-2
    • Vingerhoets J, Buelens A, Peeters M, et al. Impact of baseline NNRTI mutations on the virological response to TMC125 in the phase III clinical trials DUET-1 and DUET-2. Antivir Ther 2007; 12:S34.
    • (2007) Antivir Ther , vol.12
    • Vingerhoets, J.1    Buelens, A.2    Peeters, M.3
  • 4
    • 42149166694 scopus 로고    scopus 로고
    • Prevalence of etravirine-associated mutations in clinical samples with resistance to nevirapine and efavirenz
    • Llibre JM, Santos JR, Puig T, et al. Prevalence of etravirine-associated mutations in clinical samples with resistance to nevirapine and efavirenz. Antivir Ther 2007; 12:S74.
    • (2007) Antivir Ther , vol.12
    • Llibre, J.M.1    Santos, J.R.2    Puig, T.3
  • 5
    • 33845968601 scopus 로고    scopus 로고
    • Efficacy and safety at 48 weeks with the novel NNRTI, TMC125, and impact of baseline resistance on the virological response in study TMC125-C223
    • 13-18 August, Toronto, Canada. Abstract TUPE0061
    • Cohen C, Steinhart CR, Ward DJ, et al. Efficacy and safety at 48 weeks with the novel NNRTI, TMC125, and impact of baseline resistance on the virological response in study TMC125-C223. 16th International AIDS Conference. 13-18 August 2006. Toronto, Canada. Abstract TUPE0061.
    • (2006) 16th International AIDS Conference
    • Cohen, C.1    Steinhart, C.R.2    Ward, D.J.3
  • 6
    • 35548934864 scopus 로고    scopus 로고
    • R1206, a representative of a new class of potent diphenylether non-nucleoside reverse transcriptase inhibitors broadly active against NNRTI resistant HIV-1 variants and achieving high systemic exposures and benign safety profiles in animal species
    • Klumpp K, Dunn J, Heilek G, et al. R1206, a representative of a new class of potent diphenylether non-nucleoside reverse transcriptase inhibitors broadly active against NNRTI resistant HIV-1 variants and achieving high systemic exposures and benign safety profiles in animal species. Antivir Ther 2007; 12:S30.
    • (2007) Antivir Ther , vol.12
    • Klumpp, K.1    Dunn, J.2    Heilek, G.3
  • 7
    • 42149119569 scopus 로고    scopus 로고
    • Impact of Gag cleavage site mutations on the virological response to darunavir/ritonavir in treatment-experienced patients in POWER 1, 2 and 3
    • Dierynck I, De Meyer S, Cao-Van K, et al. Impact of Gag cleavage site mutations on the virological response to darunavir/ritonavir in treatment-experienced patients in POWER 1, 2 and 3. Antivir Ther 2007; 12:S23.
    • (2007) Antivir Ther , vol.12
    • Dierynck, I.1    De Meyer, S.2    Cao-Van, K.3
  • 8
    • 40949143135 scopus 로고    scopus 로고
    • The emerging field of HCV drug resistance
    • Koev G, Kati W. The emerging field of HCV drug resistance. Expert Opin Investig Drugs 2008; 17:303-319.
    • (2008) Expert Opin Investig Drugs , vol.17 , pp. 303-319
    • Koev, G.1    Kati, W.2
  • 9
    • 42149193158 scopus 로고    scopus 로고
    • Synergy of a hepatitis C virus (HCV) NS4A antagonist, ACH-806, in combination with HCV protease or polymerase inhibitors
    • Wyles DL, Kaihara KA, Schooley RT. Synergy of a hepatitis C virus (HCV) NS4A antagonist, ACH-806, in combination with HCV protease or polymerase inhibitors. Antivir Ther 2007; 12:S29.
    • (2007) Antivir Ther , vol.12
    • Wyles, D.L.1    Kaihara, K.A.2    Schooley, R.T.3
  • 10
    • 35549003416 scopus 로고    scopus 로고
    • Characterization of maraviroc resistance in patients failing treatment with CCR5-tropic virus in MOTIVATE 1 and MOTIVATE 2
    • Mori J, Mosley M, Lewis M, et al. Characterization of maraviroc resistance in patients failing treatment with CCR5-tropic virus in MOTIVATE 1 and MOTIVATE 2. Antivir Ther 2007; 12:S12.
    • (2007) Antivir Ther , vol.12
    • Mori, J.1    Mosley, M.2    Lewis, M.3
  • 11
    • 33847237614 scopus 로고    scopus 로고
    • Reduced maximal inhibition in phenotypic susceptibility assays indicates that viral strains resistant to the CCR5 antagonist maraviroc utilize inhibitor-bound receptor for entry
    • Westby M, Smith-Burchnell C, Mori J, et al. Reduced maximal inhibition in phenotypic susceptibility assays indicates that viral strains resistant to the CCR5 antagonist maraviroc utilize inhibitor-bound receptor for entry. J Virol 2007; 81:2359-2371.
    • (2007) J Virol , vol.81 , pp. 2359-2371
    • Westby, M.1    Smith-Burchnell, C.2    Mori, J.3
  • 12
    • 35648938560 scopus 로고    scopus 로고
    • CXCR4-using virus detected in patients receiving maraviroc in the phase III studies MOTIVATE 1 and 2 originates from a preexisting minority of CXCR4-using virus
    • Lewis M, Simpson P, Fransen S, et al. CXCR4-using virus detected in patients receiving maraviroc in the phase III studies MOTIVATE 1 and 2 originates from a preexisting minority of CXCR4-using virus. Antivir Ther 2007; 12:S65.
    • (2007) Antivir Ther , vol.12
    • Lewis, M.1    Simpson, P.2    Fransen, S.3
  • 13
    • 42149142308 scopus 로고    scopus 로고
    • In vivo emergence of HIV-1 resistance to the CCR5 antagonist vicriviroc: Findings from ACTG A5211
    • Tsibris AMN, Gulick RM, Su Z, et al. In vivo emergence of HIV-1 resistance to the CCR5 antagonist vicriviroc: findings from ACTG A5211. Antivir Ther 2007; 12:S15.
    • (2007) Antivir Ther , vol.12
    • Tsibris, A.M.N.1    Gulick, R.M.2    Su, Z.3
  • 14
    • 42149089300 scopus 로고    scopus 로고
    • HIV-1 isolates resistant to CCR5 antagonists demonstrate increased affinitv for the drug-bound coreceptor
    • Buontempo PJ, Wojcik L, Buontempo C, et al. HIV-1 isolates resistant to CCR5 antagonists demonstrate increased affinitv for the drug-bound coreceptor. Antivir Ther 2007; 12:S135.
    • (2007) Antivir Ther , vol.12
    • Buontempo, P.J.1    Wojcik, L.2    Buontempo, C.3
  • 15
    • 35548953390 scopus 로고    scopus 로고
    • Mutations in the coreceptor binding region of the HIV-1 envelope confer resistance to the CCR5 inhibitor SCH-C (SCH 351125)
    • Huang W, Wojcik L, Toma J, et al. Mutations in the coreceptor binding region of the HIV-1 envelope confer resistance to the CCR5 inhibitor SCH-C (SCH 351125). Antivir Ther 2007; 12:S134.
    • (2007) Antivir Ther , vol.12
    • Huang, W.1    Wojcik, L.2    Toma, J.3
  • 16
    • 35548950520 scopus 로고    scopus 로고
    • CCR5 binding properties of a CCR5 small-molecule inhibitor with high antiviral potency against a maraviroc-resistant HIV-1 strain
    • Jekle A, Kondru R, Ji C, et al. CCR5 binding properties of a CCR5 small-molecule inhibitor with high antiviral potency against a maraviroc-resistant HIV-1 strain. Antivir Ther 2007; 12:S13.
    • (2007) Antivir Ther , vol.12
    • Jekle, A.1    Kondru, R.2    Ji, C.3
  • 17
    • 40749144292 scopus 로고    scopus 로고
    • Current implementations of HIV genotyping algorithms are inadequate for the prediction of X4 coreceptor usage in clinical isolates from population-based V3 sequences: Approaches to improvement
    • Low A, Chan D, Dong W, et al. Current implementations of HIV genotyping algorithms are inadequate for the prediction of X4 coreceptor usage in clinical isolates from population-based V3 sequences: approaches to improvement. Antivir Ther 2007; 12:S164.
    • (2007) Antivir Ther , vol.12
    • Low, A.1    Chan, D.2    Dong, W.3
  • 18
    • 42149087103 scopus 로고    scopus 로고
    • Drug resistance at virological failure in a randomized, phase III trial of NRTI-, PI- and NNRTI-sparing regimens for initial treatment of HIV-1 infection (ACTG 5142)
    • Haubrich RH , Riddler SA, DiRienzo AG, et al. Drug resistance at virological failure in a randomized, phase III trial of NRTI-, PI- and NNRTI-sparing regimens for initial treatment of HIV-1 infection (ACTG 5142). Antivir Ther 2007; 12:S66.
    • (2007) Antivir Ther , vol.12
    • Haubrich, R.H.1    Riddler, S.A.2    DiRienzo, A.G.3
  • 19
    • 42149141221 scopus 로고    scopus 로고
    • Protease gene mutations in a trial comparing first-line lopinavir/ritonavir monotherapy to lopinavir/ritonavir + zidovudine/lamivudine (MONARK trial)
    • Delaugerre C, Flandre P, Chaix ML, et al. Protease gene mutations in a trial comparing first-line lopinavir/ritonavir monotherapy to lopinavir/ritonavir + zidovudine/lamivudine (MONARK trial). Antivir Ther 2007; 12:S84.
    • (2007) Antivir Ther , vol.12
    • Delaugerre, C.1    Flandre, P.2    Chaix, M.L.3
  • 20
    • 42149190645 scopus 로고    scopus 로고
    • Impact of high baseline resistance to approved protease inhibitors on darunavir/r virological response in treatment-experienced patients in POWER 1, 2 and 3
    • De Meyer S, Picchio G, Vangeneugden T, et al. Impact of high baseline resistance to approved protease inhibitors on darunavir/r virological response in treatment-experienced patients in POWER 1, 2 and 3. Antivir Ther 2007; 12:S89.
    • (2007) Antivir Ther , vol.12
    • De Meyer, S.1    Picchio, G.2    Vangeneugden, T.3
  • 21
    • 42149164325 scopus 로고    scopus 로고
    • Viral evolution in HIV-1 reverse transcriptase in patients receiving a holding regimen with Trizivir and tenofovir with persistent viral replication
    • Llibre JM, Bonjoch A, Iribarren JA, et al. Viral evolution in HIV-1 reverse transcriptase in patients receiving a holding regimen with Trizivir and tenofovir with persistent viral replication. Antivir Ther 2007; 12:S80.
    • (2007) Antivir Ther , vol.12
    • Llibre, J.M.1    Bonjoch, A.2    Iribarren, J.A.3
  • 22
    • 56549090099 scopus 로고    scopus 로고
    • Non-nucleoside reverse transcriptase inhibitor (NNRTI) plasma concentrations determine different NNRTI-resistance pattern in virological responders during treatment interruptions
    • Darwich L, Bellido R, Blanco A, et al. Non-nucleoside reverse transcriptase inhibitor (NNRTI) plasma concentrations determine different NNRTI-resistance pattern in virological responders during treatment interruptions. Antivir Ther 2007; 12:S73.
    • (2007) Antivir Ther , vol.12
    • Darwich, L.1    Bellido, R.2    Blanco, A.3
  • 23
    • 33845396491 scopus 로고    scopus 로고
    • A comparison of three highly active antiretroviral treatment strategies consisting of non-nucleoside reverse transcriptase inhibitors, protease inhibitors, or both in the presence of nucleoside reverse transcriptase inhibitors as initial therapy (CPCRA 058 FIRST study): A long-term randomized trial
    • MacArthur RD, Novak RM, Peng G, et al. A comparison of three highly active antiretroviral treatment strategies consisting of non-nucleoside reverse transcriptase inhibitors, protease inhibitors, or both in the presence of nucleoside reverse transcriptase inhibitors as initial therapy (CPCRA 058 FIRST study): a long-term randomized trial. Lancet 2006; 368:2125-2135.
    • (2006) Lancet , vol.368 , pp. 2125-2135
    • MacArthur, R.D.1    Novak, R.M.2    Peng, G.3
  • 24
    • 40649090528 scopus 로고    scopus 로고
    • Prevalence of low abundant drug-resistant variants by ultra-deep sequencing in chronically HIV-infected antiretroviral (ARV)-naive patients and the impact on virological outcomes
    • Simen BB, Huppler Hullsiek K, Novak RM, et al. Prevalence of low abundant drug-resistant variants by ultra-deep sequencing in chronically HIV-infected antiretroviral (ARV)-naive patients and the impact on virological outcomes. Antivir Ther 2007; 12:S149.
    • (2007) Antivir Ther , vol.12
    • Simen, B.B.1    Huppler Hullsiek, K.2    Novak, R.M.3
  • 25
    • 40649099724 scopus 로고    scopus 로고
    • Sensitive testing demonstrates a high prevalence of transmitted drug resistance among conventionally genotyped wild-type HIV-1 infections
    • Johnson JA, Li J-F, Wei X, et al. Sensitive testing demonstrates a high prevalence of transmitted drug resistance among conventionally genotyped wild-type HIV-1 infections. Antivir Ther 2007; 12:S46.
    • (2007) Antivir Ther , vol.12
    • Johnson, J.A.1    Li, J.-F.2    Wei, X.3
  • 26
    • 40649116561 scopus 로고    scopus 로고
    • Prevalence of minority quasispecies of drug-resistant HIV-1 in patients with primary HIV-1 infection in Zurich in the years 2002- 2006
    • Metzner KJ, Rauch P, von Wyl V, et al. Prevalence of minority quasispecies of drug-resistant HIV-1 in patients with primary HIV-1 infection in Zurich in the years 2002- 2006. Antivir Ther 2007; 12:S47.
    • (2007) Antivir Ther , vol.12
    • Metzner, K.J.1    Rauch, P.2    von Wyl, V.3
  • 27
    • 42149177810 scopus 로고    scopus 로고
    • High concordance between HIV-1 drug resistance genotypes generated from plasma and dried blood spots in antiretroviral-experienced patients
    • Masciotra S, Garrido C, Youngpairoj AS, et al. High concordance between HIV-1 drug resistance genotypes generated from plasma and dried blood spots in antiretroviral-experienced patients. Antivir Ther 2007; 12:S158.
    • (2007) Antivir Ther , vol.12
    • Masciotra, S.1    Garrido, C.2    Youngpairoj, A.S.3
  • 28
    • 40649102546 scopus 로고    scopus 로고
    • Application of a broadly sensitive genotyping assay using dried blood spots for surveillance of HIV-1 drug resistance in PEPFAR countries
    • McNulty A, Diallo K, Zhang J, et al. Application of a broadly sensitive genotyping assay using dried blood spots for surveillance of HIV-1 drug resistance in PEPFAR countries. Antivir Ther 2007; 12:S59.
    • (2007) Antivir Ther , vol.12
    • McNulty, A.1    Diallo, K.2    Zhang, J.3
  • 29
    • 42149160075 scopus 로고    scopus 로고
    • Factors determining efficacy of HIV-1 drug resistance genotyping from dried blood spots within an internally-controlled assay system
    • Buckton AJ, Bissett SL, Myers RE, et al. Factors determining efficacy of HIV-1 drug resistance genotyping from dried blood spots within an internally-controlled assay system. Antivir Ther 2007; 12:S159.
    • (2007) Antivir Ther , vol.12
    • Buckton, A.J.1    Bissett, S.L.2    Myers, R.E.3
  • 30
    • 33749021387 scopus 로고    scopus 로고
    • Emergence of drug resistance is associated with an increased risk of death among patients first starting HAART
    • Hogg RS, Bangsberg DR, Lima VD, et al. Emergence of drug resistance is associated with an increased risk of death among patients first starting HAART. PLoS Med 2006; 3:e356.
    • (2006) PLoS Med , vol.3
    • Hogg, R.S.1    Bangsberg, D.R.2    Lima, V.D.3
  • 31
    • 42149151032 scopus 로고    scopus 로고
    • HIV-1 drug resistance is not a predictor of increased mortality in the context of clinical care
    • Truong HM, Chen S, McFarland W, et al. HIV-1 drug resistance is not a predictor of increased mortality in the context of clinical care. Antivir Ther 2007; 12:S62.
    • (2007) Antivir Ther , vol.12
    • Truong, H.M.1    Chen, S.2    McFarland, W.3
  • 32
    • 42149126711 scopus 로고    scopus 로고
    • Frequency of transmitted drug resistance among acute and recently HIV-infected patients in North Carolina is similar to reports from more urbanized areas
    • Hurt C, McCoy S, Kerkau M, et al. Frequency of transmitted drug resistance among acute and recently HIV-infected patients in North Carolina is similar to reports from more urbanized areas. Antivir Ther 2007; 12:S55.
    • (2007) Antivir Ther , vol.12
    • Hurt, C.1    McCoy, S.2    Kerkau, M.3
  • 33
    • 33845943963 scopus 로고    scopus 로고
    • HIV-1 protease and reverse transcriptase mutations for drug resistance surveillance
    • Shafer RW, Rhee SY, Pillay D, et al. HIV-1 protease and reverse transcriptase mutations for drug resistance surveillance. AIDS 2007; 21:215-223.
    • (2007) AIDS , vol.21 , pp. 215-223
    • Shafer, R.W.1    Rhee, S.Y.2    Pillay, D.3
  • 34
    • 42149116928 scopus 로고    scopus 로고
    • Increasing prevalence of HIV-1 non-B subtypes in the US and implications for protease inhibitor resistance mutation scores
    • Kagan R, Winters M, Li L, Lewinski M, et al. Increasing prevalence of HIV-1 non-B subtypes in the US and implications for protease inhibitor resistance mutation scores. Antivir Ther 2007; 12:S51.
    • (2007) Antivir Ther , vol.12
    • Kagan, R.1    Winters, M.2    Li, L.3    Lewinski, M.4
  • 35
    • 40649113790 scopus 로고    scopus 로고
    • Changes in the regional prevalence of HIV-1 drug resistance-associated mutations and in the prevalence of non-clade B sub types in antiretroviral therapy-naive HIV-infected patients in the United States from 2000-2006
    • Ross LL, Williams V, Wine B, et al. Changes in the regional prevalence of HIV-1 drug resistance-associated mutations and in the prevalence of non-clade B sub types in antiretroviral therapy-naive HIV-infected patients in the United States from 2000-2006. Antivir Ther 2007; 12:S54.
    • (2007) Antivir Ther , vol.12
    • Ross, L.L.1    Williams, V.2    Wine, B.3
  • 36
    • 42149086532 scopus 로고    scopus 로고
    • Sustained restriction of viral diversity following interruption of antiretroviral treatment
    • Joos B, Fischer M, Kuster H, et al. Sustained restriction of viral diversity following interruption of antiretroviral treatment. Antivir Ther 2007; 12:S104.
    • (2007) Antivir Ther , vol.12
    • Joos, B.1    Fischer, M.2    Kuster, H.3
  • 37
    • 42149105663 scopus 로고    scopus 로고
    • Impact of HR1 enfuvirtide resistance mutations on sensitivity to HR2-directed neutralizing antibodies
    • Barry AP, Stanfield-Oakley SA, Mosier SM, Greenberg ML. Impact of HR1 enfuvirtide resistance mutations on sensitivity to HR2-directed neutralizing antibodies. Antivir Ther 2007; 12:S114.
    • (2007) Antivir Ther , vol.12
    • Barry, A.P.1    Stanfield-Oakley, S.A.2    Mosier, S.M.3    Greenberg, M.L.4
  • 38
    • 16244380203 scopus 로고    scopus 로고
    • Enfuvirtide resistance mutations: Impact on human immunodeficiency virus envelope function, entry inhibitor sensitivity, and virus neutralization
    • Reeves JD, Lee FH, Miamidian JL, et al. Enfuvirtide resistance mutations: impact on human immunodeficiency virus envelope function, entry inhibitor sensitivity, and virus neutralization. J Virol 2005; 79:4991-4999.
    • (2005) J Virol , vol.79 , pp. 4991-4999
    • Reeves, J.D.1    Lee, F.H.2    Miamidian, J.L.3
  • 39
    • 33748684791 scopus 로고    scopus 로고
    • Specific mutations in HIV-1 gp41 are associated with immunological success in HIV-1-infected patients receiving enfuvirtide treatment
    • Aquaro S, D'Arrigo R, Svicher V, et al. Specific mutations in HIV-1 gp41 are associated with immunological success in HIV-1-infected patients receiving enfuvirtide treatment. J Antimicrob Chemother 2006; 58:714-722.
    • (2006) J Antimicrob Chemother , vol.58 , pp. 714-722
    • Aquaro, S.1    D'Arrigo, R.2    Svicher, V.3
  • 40
    • 42149177237 scopus 로고    scopus 로고
    • How HIV-1 selects copackaged RNAs: Implication for antiviral strategies targeting RNA dimerization initiation signal
    • Moore MD, Fu W, Nikolaitchik O, et al. How HIV-1 selects copackaged RNAs: implication for antiviral strategies targeting RNA dimerization initiation signal. Antivir Ther 2007; 12:S95.
    • (2007) Antivir Ther , vol.12
    • Moore, M.D.1    Fu, W.2    Nikolaitchik, O.3
  • 41
    • 37549060149 scopus 로고    scopus 로고
    • A novel genetic pathway involving L76V and M46I leading to lopinavir/r resistance
    • Nijhuis M, Wensing AMJ, Bierman W, et al. A novel genetic pathway involving L76V and M46I leading to lopinavir/r resistance. Antivir Ther 2007; 12:S140.
    • (2007) Antivir Ther , vol.12
    • Nijhuis, M.1    Wensing, A.M.J.2    Bierman, W.3
  • 42
    • 42149149323 scopus 로고    scopus 로고
    • Silent mutations at RT codons 65 and 66 are very strongly associated with treatment and drug resistance and are implicated in reverse transcription efficiency
    • Harrigan PR, Chihwei Sheen T, Wynhoven B, et al. Silent mutations at RT codons 65 and 66 are very strongly associated with treatment and drug resistance and are implicated in reverse transcription efficiency. Antivir Ther 2007; 12:S126.
    • (2007) Antivir Ther , vol.12
    • Harrigan, P.R.1    Chihwei Sheen, T.2    Wynhoven, B.3
  • 43
    • 42149158303 scopus 로고    scopus 로고
    • In vitro molecular characterization of the development of the K65R and M184V mutations in subtype C HIV-1
    • Coutsinos D, Invernizzi CF, Xu H, et al. In vitro molecular characterization of the development of the K65R and M184V mutations in subtype C HIV-1. Antivir Ther 2007; 12:S127.
    • (2007) Antivir Ther , vol.12
    • Coutsinos, D.1    Invernizzi, C.F.2    Xu, H.3
  • 44
    • 33745853539 scopus 로고    scopus 로고
    • HIV-1 subtype C viruses rapidly develop K65R resistance to tenofovir in cell culture
    • Brenner BG, Oliveira M, Doualla-Bell F, et al. HIV-1 subtype C viruses rapidly develop K65R resistance to tenofovir in cell culture. AIDS 2006; 20:F9-F13.
    • (2006) AIDS , vol.20
    • Brenner, B.G.1    Oliveira, M.2    Doualla-Bell, F.3
  • 45
    • 33845242455 scopus 로고    scopus 로고
    • High prevalence of the K65R mutation in human immunodeficiency virus type 1 subtype C isolates from infected patients in Botswana treated with didanosine-based regimens
    • Doualla-Bell F, Avalos A, Brenner BG, et al. High prevalence of the K65R mutation in human immunodeficiency virus type 1 subtype C isolates from infected patients in Botswana treated with didanosine-based regimens. Antimicrob Agents Chemother 2006; 50:4182-4185.
    • (2006) Antimicrob Agents Chemother , vol.50 , pp. 4182-4185
    • Doualla-Bell, F.1    Avalos, A.2    Brenner, B.G.3
  • 46
    • 37849005500 scopus 로고    scopus 로고
    • HIV-1 reverse transcriptase mutations A371V and Q509L decrease DNA-dependent RNase H cleavage and increase the rate of AZT-MP excision
    • Brehm J, Koontz D, Sluis-Cremer N, Mellors J. HIV-1 reverse transcriptase mutations A371V and Q509L decrease DNA-dependent RNase H cleavage and increase the rate of AZT-MP excision. Antivir Ther 2007; 12:S124
    • (2007) Antivir Ther , vol.12
    • Brehm, J.1    Koontz, D.2    Sluis-Cremer, N.3    Mellors, J.4
  • 47
    • 33846411113 scopus 로고    scopus 로고
    • AZT selects mutations in the connection (A371V) and RNase H (Q509L) domains of RT that increase AZT resistance in combination with TAMs and reduce susceptibility to other NRTIs
    • Brehm J, Koontz D, Pathak D, et al. AZT selects mutations in the connection (A371V) and RNase H (Q509L) domains of RT that increase AZT resistance in combination with TAMs and reduce susceptibility to other NRTIs. Antivir Ther 2006; 11:S141.
    • (2006) Antivir Ther , vol.11
    • Brehm, J.1    Koontz, D.2    Pathak, D.3
  • 48
    • 34547105526 scopus 로고    scopus 로고
    • Selection of mutations in the connection and RNase H domains of human immunodeficiency virus type 1 reverse transcriptase that increase resistance to 3′-azido-3′- dideoxythymidine
    • Brehm JH, Koontz D, Meteer JD, et al. Selection of mutations in the connection and RNase H domains of human immunodeficiency virus type 1 reverse transcriptase that increase resistance to 3′-azido-3′- dideoxythymidine. J Virol 2007; 81:7852-7859.
    • (2007) J Virol , vol.81 , pp. 7852-7859
    • Brehm, J.H.1    Koontz, D.2    Meteer, J.D.3
  • 49
    • 42149097816 scopus 로고    scopus 로고
    • Probing the mechanism by which connection domain mutations enhance AZT resistance: Mutational analysis of the RNase H primer grip
    • Delviks-Frankenberry KA, Nikolenko GN, Barr R, Pathak VK. Probing the mechanism by which connection domain mutations enhance AZT resistance: mutational analysis of the RNase H primer grip. Antivir Ther 2007; 12:S125.
    • (2007) Antivir Ther , vol.12
    • Delviks-Frankenberry, K.A.1    Nikolenko, G.N.2    Barr, R.3    Pathak, V.K.4
  • 50
    • 34250811908 scopus 로고    scopus 로고
    • Mutations in human immunodeficiency virus type 1 RNase H primer grip enhance 3′-azido-3′-deoxythymidine resistance
    • Delviks-Frankenberry KA, Nikolenko GN, Barr R, Pathak VK. Mutations in human immunodeficiency virus type 1 RNase H primer grip enhance 3′-azido-3′-deoxythymidine resistance. J Virol 2007; 81:6837-6845.
    • (2007) J Virol , vol.81 , pp. 6837-6845
    • Delviks-Frankenberry, K.A.1    Nikolenko, G.N.2    Barr, R.3    Pathak, V.K.4
  • 51
    • 33846063300 scopus 로고    scopus 로고
    • Mutations in the connection domain of HIV-1 reverse transcriptase increase 3′-azido-3′-deoxythymidine resistance
    • Nikolenko GN, Delviks-Frankenberry KA, Palmer S, et al. Mutations in the connection domain of HIV-1 reverse transcriptase increase 3′-azido-3′-deoxythymidine resistance. Proc Natl Acad Sci U S A 2007; 104:317-322.
    • (2007) Proc Natl Acad Sci U S A , vol.104 , pp. 317-322
    • Nikolenko, G.N.1    Delviks-Frankenberry, K.A.2    Palmer, S.3
  • 52
    • 42149164324 scopus 로고    scopus 로고
    • Competition with the nucleic acid substtate can present an obstacle in the development of RNase H active site inhibitors
    • Beilhartz G, Tchesnokov E, Bermingham A, et al. Competition with the nucleic acid substtate can present an obstacle in the development of RNase H active site inhibitors. Antivir Ther 2007; 12:S123.
    • (2007) Antivir Ther , vol.12
    • Beilhartz, G.1    Tchesnokov, E.2    Bermingham, A.3
  • 53
    • 42149162256 scopus 로고    scopus 로고
    • Circumventing drug resistance: Using the substrate envelope hypothesis to develop robust novel HIV-1 protease inhibitors
    • Nalam MNL, Ali A, Reddy K, et al. Circumventing drug resistance: using the substrate envelope hypothesis to develop robust novel HIV-1 protease inhibitors. Antivir Ther 2007; 12:S138.
    • (2007) Antivir Ther , vol.12
    • Nalam, M.N.L.1    Ali, A.2    Reddy, K.3
  • 54
    • 34249275362 scopus 로고    scopus 로고
    • Design of mutation-resistant HIV protease Inhibitors with the substrate envelope hypothesis
    • Chellappan S, Kiran Kumar Reddy GS, Ali A, et al. Design of mutation-resistant HIV protease Inhibitors with the substrate envelope hypothesis. Chem Biol Drug Des 2007; 69:298-313.
    • (2007) Chem Biol Drug Des , vol.69 , pp. 298-313
    • Chellappan, S.1    Kiran2    Kumar Reddy, G.S.3    Ali, A.4
  • 55
    • 34250794023 scopus 로고    scopus 로고
    • Evaluation of the substrate envelope hypothesis for inhibitors of HIV-1 protease
    • Chellappan S, Kairys V, Fernandes MX, et al. Evaluation of the substrate envelope hypothesis for inhibitors of HIV-1 protease. Proteins 2007; 68:561-567.
    • (2007) Proteins , vol.68 , pp. 561-567
    • Chellappan, S.1    Kairys, V.2    Fernandes, M.X.3
  • 56
    • 33645767675 scopus 로고    scopus 로고
    • Substrate envelope and drug resistance: Crystal structure of RO1 in complex with wild-type human immunodeficiency virus type 1 protease
    • Prabu-Jeyabalan M, King NM, Nalivaika EA, et al. Substrate envelope and drug resistance: crystal structure of RO1 in complex with wild-type human immunodeficiency virus type 1 protease. Antimicrob Agents Chemother 2006; 50:1518-1521.
    • (2006) Antimicrob Agents Chemother , vol.50 , pp. 1518-1521
    • Prabu-Jeyabalan, M.1    King, N.M.2    Nalivaika, E.A.3
  • 57
    • 33645227102 scopus 로고    scopus 로고
    • Mechanism of substrate recognition by drug-resistant human immunodeficiency virus type 1 protease variants revealed by a novel structural intermediate
    • Prabu-Jeyabalan M, Nalivaika EA, Romano K, Schiffer CA. Mechanism of substrate recognition by drug-resistant human immunodeficiency virus type 1 protease variants revealed by a novel structural intermediate. J Virol 2006; 80:3607-3616.
    • (2006) J Virol , vol.80 , pp. 3607-3616
    • Prabu-Jeyabalan, M.1    Nalivaika, E.A.2    Romano, K.3    Schiffer, C.A.4


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.